AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05313178 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Bacillus Coagulans GBI-30, 6086
Description: In a randomized, double-blind, crossover fashion, study participants will supplement on a daily basis for two weeks during one study period with a 25-gram dose of either milk protein concentrate or a 25-gram dose of milk protein concentrate with bacillus coagulans GBI-30, 6086. Each dose will be ingested at the same time of day with 8 - 12 fluid ounces of cold tap water. All participants will be required to complete a supplementation log to document when each dose of their assigned protein is consumed. Upon completion of their first assigned study protocol period, participants will observe a three-week washout period by returning to their normal dietary intake and physical activity habits before beginning supplementation for the remaining study period.
Study NCT04433884 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endotracheal intubation using a laryngoscope
Description: Patients will undergo intubation using 2 different types of laryngoscopes and their hemodynamic response would be recorded
Study NCT00528489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-12
Description: Cytokine injection
Study NCT00528489 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IL-15
Description: Cytokine injection
Study NCT01017770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artesunate-amodiaquine
Description: Coformulated AQ+AS by Sanofi-Aventis has been pre-qualified by WHO in 2008. It is administered once daily for three consecutive days, and it is available in three different dosages (25mg/67.5mg; 50mg/135mg; 100mg/270mg)
Study NCT01017770 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine
Description: Artemether-lumefantrine by Novartis was the first fixed-dose ACT that was prequalified by WHO in April 2004. A 3-day, 6-dose regimen of AL is recommended for infants and children weighing 5-35 kg and adults weighing > 35 kg.
Study NCT02754310 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Variation of scenarios
Description: Three different scenarios of pediatric asthma exacerbations: a mild exacerbation, a moderate exacerbation, and a severe exacerbation.
Study NCT02754310 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Repeated scenarios
Description: The same scenario of a moderate pediatric asthma exacerbation is repeated three times.
Study NCT04468633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Baerveldt 350 implant
Description: The Baerveldt implant is an FDA-approved silicone, non-valved implant.
Study NCT04468633 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ahmed ClearPath 350 implant
Description: The Ahmed ClearPath is a non-valved glaucoma drainage device.
Study NCT03643705 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multi-component intervention
Description: 4 components as described
Study NCT03643705 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: General prevention education
Description: General education as described
Study NCT01498445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dasatinib
Description: Starting Dose: 100 mg by mouth once daily of a 28 day cycle.
Study NCT00638222 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carvedilol and Placebo
Description: All enrolled participants were randomized to receive Carvedilol or Placebo in a 2-way crossover design. Each intervention was administered over 8 weeks before switching to the alternative intervention. The study was terminated early, and data were not unblinded so participants cannot be reported separately.
Study NCT02423343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Galunisertib
Description: Administered orally
Study NCT04288596 — intervention group
Intervention type: OTHER
Intervention: Participants undergoing ACHD intervention
Description: Participants will receive standard of care for their ACHD intervention.
Study NCT02213796 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Meropenem
Study NCT03517852 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Human Intravital Microscopy
Description: Intravital microscopy (IVM) allows real-time, direct visualization of microscopic blood vessels and calculation of blood flow.
Study NCT03781297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Narrative Exposure Therapy
Description: Narrative Exposure Therapy attempts to place the trauma within a narrative of the person's life. Anecdotal evidence of using this approach in the homeless population is that constructing an autobiography helps to give meaning to their problems and provide the initial steps in constructing a core sense of belonging and identity. Six sessions of individual therapy allows for participants to work with a therapist one-on-one to position their experiences of trauma within their life story.
Study NCT03781297 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Genealogical Services
Description: At the start of their involvement in the, study participants randomized to this group will be provided with the option to access services from a professional genealogist, to trace their family history. Participants will be made aware of the fact that new family information will be revealed through this process, and also be informed of the standard methods that will be used to extract this information which could involve research through publicly available historical records or voluntary DNA testing.
Study NCT02863484 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: pealing of the outer layer of the cavernous sinus
Study NCT03363581 — intervention group
Intervention type: BEHAVIORAL
Intervention: Food Preference
Description: Buffet meal to assess food preference
Study NCT05808556 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sticker pads containing lavender and ylang ylang oil
Description: The sticker pad group attached an sticker pad (0.3% lavender oil and 0.7% ylang ylang oil) to their shirt, close to the right side of the neck, for 14 days,
Study NCT05808556 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo group attached a sticker pad without lavender and ylang ylang oil to their shirt, close to the right side of the neck, for 14 days.
Study NCT03800069 — intervention group
Intervention type: DEVICE
Intervention: Group K Diagnostic point of care device
Description: Arm 1 will have a finger prick sample collected to test the ability of Group K Diagnostic point of care device and app to identify liver function values.
Study NCT03114956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gauze
Description: Implant surface will be wiped with sterile gauze soaked alternatively in sterile saline and CHX (5 times)
Study NCT03114956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Titanium brush
Description: Titanium brush: Titanium brush (TiBrush, Straumann, Switzerland) mounted on an oscillating hand piece will be used for 1 minute.
Study NCT03114956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Air powder abrasion
Description: Air powder abrasion: One minute of air powder abrasion using Glycine prophy powder (Prophy Jet, Dentsply, USA) with overlapping passes form apical to coronal direction for 1 minute.
Study NCT03114956 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Comprehensive
Description: A comprehensive treatment including the use of titanium brush and air powder abrasion (as described above) and 30 seconds etching with 9.6% HF acid gel (Premier, USA) applied with a micro-applicator tip (Unipack Medical, USA), followed by copious irrigation with sterile saline.
Study NCT02423343 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Administered IV
Study NCT02142959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Lotion 0.5%
Description: Omaveloxolone lotion 0.5% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Study NCT02142959 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omaveloxolone Lotion 3%
Description: Omaveloxolone lotion 3% will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Study NCT01498445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting Dose (less intensive group) Schedule A: 10 mg/m2 by vein daily for 10 days of a 28 day cycle.
Study NCT03616834 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tomivosertib (eFT-508)
Description: Tomivosertib (eFT-508) is a novel, small-molecule investigational drug being developed by eFFECTOR Therapeutics, as an antitumor therapy that acts by selectively inhibiting mitogen-activated protein kinase (MAPK)-interacting serine/threonine kinase (MNK)1 and MNK 2.
Study NCT01936779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary supplement: fatty acid
Description: Consumption of n-3 fatty acids for 8 weeks
Study NCT01936779 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Dietary supplement: fatty acid
Description: Consumption of olive oil for 8 weeks.
Study NCT02142959 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Lotion
Description: Lotion vehicle manufactured to mimic RTA 408 lotion will be applied topically twice-daily, for up to 13 weeks, during the course of radiation therapy
Study NCT02142959 — intervention group
Intervention type: RADIATION
Group type: PLACEBO_COMPARATOR
Intervention: 3D conformal radiation therapy
Description: 45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
Study NCT01063478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RAD001 (in addition to standard radiation and chemotherapy)
Description: Standard radiation and chemotherapy (cisplatin and pemetrexed) + RAD001
Study NCT04625920 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SootheVR: AppliedVR, Los Angeles, California
Description: a head-mounted display
Study NCT00149292 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2140023
Study NCT02142959 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 3D conformal radiation therapy
Description: 45 50.4 Gy in 1.8 Gy per day, in addition to 10 - 16 Gy boost or 46 - 50 Gy in 2 Gy per day, in addition to 10 - 16 Gy boost, at the physician's discretion
Study NCT02049814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Metformin tablets
Study NCT02049814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Metformin tablets
Study NCT02049814 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Voglibose
Description: Voglibose tablets
Study NCT02049814 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acarbose
Description: Acarbose tablets
Study NCT00737906 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical turbinate reduction procedure
Description: Surgical turbinate reduction using the COBLATION device
Study NCT02027987 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valproate acid
Description: valproate acid is a common drug which is applied for epilepsy prevention and treatment.
Study NCT02566382 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: arthroscopy arthrodesis of the shoulder
Description: The shoulder surgery will be realized under arthroscopy only
Study NCT04731090 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
Description: IV fluoroquinolone 1 hour preoperatively and oral antibiotics for 24h postoperatively.
Study NCT00149292 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: olanzapine
Study NCT00149292 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Study NCT04371614 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Prime Time Sister Circle
Description: The PTSC is a multi-faceted, facilitated, curriculum- and community-based, intensive, support group intervention with 25-30 mid-life African American women per group.
Study NCT01886274 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Transcranial direct current stimulation
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
Study NCT01886274 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial direct current stimulation
Description: tDCS involves application of very low amplitude direct current via surface scalp electrodes. The applied current modifies the transmembrane neuronal potential and thus influences the level of excitability. Depending on the polarity of active electrodes tDCS can increase or decrease the cortical excitability. The cathodal tDCS decrease the excitability, in this study a constant current of 2 mA intensity was applied for 20 min.
Study NCT06002295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chlorhexidine Topical Cream
Description: After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day.
Study NCT06002295 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylated Spirit
Description: After approval from the hospital ethical committee, neonates fulfilling inclusion and exclusion criteria were selected. Written informed consent was obtained from the parents. Full instructions to avoid confounding variables like maintaining temperature and hygiene of newborn, frequent diaper change, avoidance of herbal tonics and cow milk; are given to mothers.~In group A 4% chlorhexidine was applied generously over cord along with base of cord stump and surrounding skin thrice a day. In group B clean cotton swab dipped in methylated spirit was used to clean cord along with cord clamps and base thrice a day.
Study NCT03853577 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: TMS/EEG
Description: navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
Study NCT03853577 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: TMS/EEG
Description: navigated TMS/high-density(hd)-EEG to directly stimulate defined cortical areas and investigate quantitatively the level of consciousness in psilocybin-induced altered brain states
Study NCT05812105 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Healthy Buddy Program
Description: The Healthy Buddy Program is a community-based initiative that pairs college students with transportation disadvantaged, community- dwelling older adults age 65 and older. The Spanish-language Healthy Buddy Program was developed to measure the transportation and health challenges of Hispanic/Latino older adults and determine the efficacy of the adapted HB program model.
Study NCT04731090 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Urine culture, antibiotic prophylaxis and hydrophilic-coated ureteral access sheaths
Description: Patients had urine culture 10 days before the procedure. In addition to the antibiotic prophylaxis, hydrophilic-coated ureteral access sheaths were systematically used.
Study NCT00313885 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: eplivanserin (SR46349)
Description: oral administration
Study NCT00313885 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: oral administration
Study NCT01503723 — intervention group
Intervention type: OTHER
Intervention: Determined by intended physician
Description: We perform a prospective observational study. All the treatment for the patients are determined by intended physicians.
Study NCT02447536 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Denmark 1331 (Statens Serum Institute)
Description: See above
Study NCT02447536 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: BCG-Russia-I (Serum Institute of India)
Description: See above
Study NCT03542136 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: VibrosSense Meter®
Description: A multi frequency tactilometry device to evaluate the vibrotactile sense to indicate the underlying (Oxaliplatin induced poly neuropathy) OIPN and then compare the results with the results of CTCAE (Common toxicity criteria of adverse events) assessment tool evaluation.
Study NCT01498445 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Description: Starting Dose (more intensive group) Schedule B: 20 mg/m2 by vein daily for 10 days of a 28 day cycle.
Study NCT00161434 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: valacyclovir
Description: 1 gram daily for 8 weeks
Study NCT00161434 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: matching placebo for 8 weeks
Study NCT03994900 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Blood sampling for HbNO assessment
Description: Blood sampling
Study NCT02513810 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BioFreedom with 1 month DAPT
Description: The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be continued for 1 month.
Study NCT02513810 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BioMatrix or Ultimaster with 6 to 12 months DAPT
Description: The cath lab will follow site standard operating procedures for PTCA and stenting. Information will be collected and recorded on the treated study vessel including angiographic parameters. Dual antiplatelet therapy after PCI will be the duration of dual antiplatelet therapy will be 6 to 12 months at the discretion of the interventionist.
Study NCT02564913 — intervention group
Intervention type: OTHER
Intervention: clinical evaluation
Study NCT02766803 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Simvastatin and micronized trans-resveratrol
Study NCT02766803 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Simvastatin and micronized trans-resveratrol
Study NCT02863484 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: surgery
Description: pealing of the outer layer of the cavernous sinus
Study NCT01856530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: Liquid metered-dose nasal spray, 24 IU, administered once
Study NCT01856530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matched placebo nasal spray
Study NCT03300947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 100 mcg/kg
Description: Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms).
Study NCT03300947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Psilocybin 300 mcg/kg
Description: Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms).
Study NCT03300947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Psilocybin 300 mcg/kg
Description: Psilocybin belongs to the class of hallucinogen or psychedelic drugs. It is one of the major psychoactive components in mushrooms of the Psilocybe genus (magic mushrooms).
Study NCT03300947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lorazepam 1 mg
Description: A medication used to treat anxiety belonging to a class of drugs known as benzodiazepines, which act on the central nervous system to produce a calming effect. This drug works by enhancing the effects of a certain natural chemical in the body (GABA).
Study NCT02753595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2 as intravenous (IV) infusion on Day 1 and 8 of 21-day cycle
Study NCT02753595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Eribulin mesylate will be administered at 1.4 mg/m\^2 or 1.1 mg/m\^2, depending on RP2D, as IV infusion on Day 1 and 8 of each 21-day cycle
Study NCT02753595 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin mesylate
Description: Eribulin mesylate will be administered at 1.4 mg/m\^2 as IV infusion on Day 1 and 8 of 21-day cycle
Study NCT02753595 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Biologic: PEGylated recombinant human hyaluronidase (PEGPH20)
Description: PEGPH20 will be administered at 3.0 mcg/kg or 1.6 mcg/kg as IV infusion on Day -1 and 7 of 21-day cycle